TLC-2716

TLC-2716 is an experimental drug and LXR inverse agonist that reduced triglycerides and remnant cholesterol in a clinical trial.[1][2]

References

  1. ↑ Staff, ScienceAlert (9 February 2026). "'Remnant' Cholesterol Cut by More Than 60 Percent in New Drug Trial". ScienceAlert. Retrieved 11 February 2026.
  2. ↑ Li, Xiaoxu; Benegiamo, Giorgia; Vijayakumar, Archana; Sroda, Natalie; Kimura, Masaki; Huss, Ryan S.; Weng, Steve; Murakami, Eisuke; Kirby, Brian J.; von Alvensleben, Giacomo V. G.; Kremoser, Claus; Gane, Edward J.; Takebe, Takanori; Myers, Robert P.; Subramanian, G. Mani; Auwerx, Johan (16 January 2026). "An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial". Nature Medicine: 1–11. doi:10.1038/s41591-025-04169-6. ISSN 1546-170X.